Sartorius AG

euro adhoc: Sartorius AG
Financial Figures/Balance Sheet
Group sales revenue rose 9.2%
EBITDA improved 18.1% to EUR49.3 million
EBIT up 26.4% to EUR35.0 million
Earnings per share rose from EUR0.79 to EUR1.11
Capital expenditures doubled
Po

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

17.10.2006

During the first nine months of fiscal 2006, sales revenue of the Sartorius Group rose 9.2% (currency-adjusted: +9.0%) to EUR386.0 million (previous year: EUR353.5 mn). In the Biotechnology Division, sales revenue climbed 10.1% (currency-adjusted: +9.9%) to EUR203.7 million (previous year: EUR185.0 mn); in the Mechatronics Division, 8.2% (currency-adjusted: +8.1%) to EUR182.3 million (previous year: EUR168.5 mn). Primarily because of the positive development in the Mechatronics Division, Group order intake grew 3.9% (currency-adjusted: +3.7%) to EUR379.4 million (previous year: EUR365.3 mn).

Group earnings before interest, taxes, depreciation and amortization (EBITDA) increased 18.1% to EUR49.3 million (previous year: EUR41.7 mn). Earnings before interest and taxes (EBIT) surged 26.4% to EUR35.0 million (EUR27.7 mn); as a result, the EBIT margin improved from 7.8% to 9.1%. For the Biotechnology Division, EBIT soared 42.2% from EUR16.2 million to EUR23.1 million, whereas for the Mechatronics Division, EBIT at EUR11.9 million was slightly higher than the year-earlier figure (EUR11.4 mn) and already included nearly all the full-year 2006 costs budgeted for the expansion of Sartorius locations in China, India and Germany. Net profit shot up 39.4% to EUR18.9 million (EUR13.5 mn); accordingly, earnings per share were EUR1.11 (EUR0.79). In comparison to the previous year, capital expenditures roughly doubled to EUR20.4 million (EUR10.0 mn). Net cash flow at EUR10.6 million (EUR15.8 mn) was significantly positive.

The company confirms its targets of increasing full-year sales revenue by approximately 7% in constant currencies and of achieving an EBIT of about 10% of sales revenue, as concretized after the first half. In fiscal 2007, the company intends to continue its growth trend and increase the profitability of the Sartorius Group to an EBIT of 11% of sales revenue.

@@start.t2@@end of announcement                                                 euro adhoc 17.10.2006 20:55:44
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Andreas Wiederhold
Phone +49.551.308.1668
andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN:      DE0007165607
WKN:        716560
Index:    CDAX, Prime All Share, Technologie All Share
Börsen:  Frankfurter Wertpapierbörse / official dealing/prime standard
              Börse Berlin-Bremen / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Bayerische Börse / free trade
              Niedersächsische Börse zu Hannover / official dealing



Weitere Meldungen: Sartorius AG

Das könnte Sie auch interessieren: